Market Exclusive

Achieve Life Sciences Inc (NASDAQ:ACHV) has coverage initiated with a Buy rating

Analyst Ratings For Achieve Life Sciences Inc (NASDAQ:ACHV)

Today, Maxim Group initiated coverage on Achieve Life Sciences Inc (NASDAQ:ACHV) with a Buy.

There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Achieve Life Sciences Inc (NASDAQ:ACHV) is Buy with a consensus target price of $20.00 per share, a potential 649.06% upside.

Some recent analyst ratings include

About Achieve Life Sciences Inc (NASDAQ:ACHV)
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. Read More…

Recent Trading Activity for Achieve Life Sciences Inc (NASDAQ:ACHV)
Shares of Achieve Life Sciences Inc closed the previous trading session at 2.67 up +0.020 0.75% with 2.64 shares trading hands.

Exit mobile version